Search Results
Your search for ,sIX matches 2928 pages
Showing 1 - 50Adjuvant Atezolizumab and mFOLFOX6 in Stage III Mismatch Repair–Deficient Colon Cancer
As reported in The New England Journal of Medicine by Sinicrope et al, the phase III ATOMIC trial has shown that the addition of adjuvant atezolizumab to mFOLFOX6 (modified fluorouracil, oxaliplatin, and leucovorin) improved disease-free survival in patients with resected stage III mismatch...
AI Model for Predicting Oncotype DX 21-Gene Recurrence Score
As reported in The Lancet Oncology, Shamai et al have developed an artifical intelligence (AI) model based on digital histopathology slide images and clinical features to predict the Oncotype DX 21-gene recurrence score (RS) in patients with hormone receptor–positive, HER2-negative invasive breast...
AI Model Classifies Challenging Thymic Epithelial Tumors
A deep learning model can diagnose thymic epithelial tumors with high sensitivity for thymic carcinoma detection, according to findings published in Annals of Oncology. The researchers suggested that the tool could be used to improve diagnostic consistency and support decision-making in settings...
FDA Approves Chemoimmunotherapy Regimen for Hodgkin Lymphoma
On March 20, the U.S. Food and Drug Administration (FDA) approved nivolumab (Opdivo) with doxorubicin, vinblastine, and dacarbazine (AVD) for adult and pediatric patients aged 12 years and older with previously untreated stage III or IV classical Hodgkin lymphoma. The FDA also granted traditional...
For Most Men With Prostate Cancer, Hormone Therapy With Postprostatectomy Radiotherapy Confers No Survival Benefit
Adding hormone therapy to postprostatectomy radiotherapy may provide little survival benefit for most men with prostate cancer, especially those with very low prostate-specific antigen (PSA) levels before treatment. In the study, reported at the 2026 ASCO Genitourinary Cancers Symposium,1 men with...
Metastatic Uveal Melanoma: Nivolumab/Ipilimumab Plus Percutaneous Hepatic Perfusion
In a Dutch single-center phase II trial (CHOPIN) reported in The Lancet Oncology, van den Hoek et al found that the addition of nivolumab and ipilimumab to percutaneous hepatic perfusion improved progression-free survival in patients with metastatic uveal melanoma. Study Details Seventy-six...
Five-Year Outcomes With First-Line Nivolumab Plus Ipilimumab in Unresectable Pleural Mesothelioma
As reported in the Journal of Clinical Oncology by Scherpereel et al, 5-year findings from the phase III CheckMate 743 trial showed continued overall survival benefit of first-line nivolumab plus ipilimumab vs chemotherapy in patients with unresectable pleural mesothelioma. Study Details In the...
Short-Term Vaginal Estrogen Therapy Does Not Increase Risks of Endometrial Cancer Recurrence
Short-term exposure to low-dose vaginal estrogen therapy may relieve some symptoms of menopause for younger survivors of endometrial cancer without increasing the risk of endometrial cancer recurrence, according to findings from a study published in Menopause. “Early detection and improved,...
Addition of Hormone Therapy to Postoperative Radiotherapy in Prostate Cancer
In an individual patient data meta-analysis reported at the 2026 ASCO Genitourinary Cancers Symposium (Abstract 305) and simultaneously published in The Lancet, Kishan et al found no apparent overall survival benefit of adding hormone therapy in patients undergoing postoperative radiotherapy after...
Skin Fluorescent Imaging Shows High Sensitivity, Specificity for Discriminating Melanoma Lesions
Skin fluorescent imaging showed high sensitivity and specificity for the discrimination of low- and high-risk lesions, demonstrating an alternative, noninvasive approach to melanoma biopsies, according to findings from a phase II trial published in JAAD International. “By identifying the molecular ...
MRI-Based Neoadjuvant Chemotherapy Duration in HER2-Positive Breast Cancer
In a Dutch phase II study (TRAIN-3) reported in The Lancet Oncology, Louis et al found that magnetic resonance imaging (MRI)-guided optimization of duration of neoadjuvant chemotherapy was associated with favorable event-free survival in patients with stage II to III HER2-positive breast cancer....
First Results of Phase III OLYMPIA-3: Odronextamab Plus CHOP in Untreated DLBCL
The bispecific antibody odronextamab plus standard CHOP (cyclophosphamide, vincristine, doxorubicin, prednisone) chemotherapy yielded robust and durable responses in treatment-naive patients with diffuse large B-cell lymphoma (DLBCL), based on the first results of the phase III OLYMPIA-3 study...
Metastasis-Directed Therapy in Oligometastatic Prostate Cancer
In an individual patient data meta-analysis (WOLVERINE) reported in The Lancet Oncology, Tang et al found that the addition of metastasis-directed therapy (MDT) to standard of care (SOC) was associated with benefits in patients with oligometastatic prostate cancer. Study Details A systematic review ...
Neoadjuvant Taxane Plus Trastuzumab and Pertuzumab With or Without Carboplatin in HER2-Positive Breast Cancer
In a Chinese phase III trial (neoCARHP) reported in the Journal of Clinical Oncology, Gao et al found that neoadjuvant therapy with a taxane plus trastuzumab and pertuzumab (THP) was noninferior in pathologic complete response (pCR) compared with THP plus carboplatin (TCbHP) in patients with stage...
FDA Approves Labeling Changes to Menopausal Hormone Therapy Products
The U.S. Food and Drug Administration (FDA) has approved drug labeling changes to six menopausal hormone therapy products, also known as hormone replacement therapy (HRT), to clarify risk considerations for these drugs. Specifically, risk statements related to cardiovascular disease, breast cancer, ...
GIMEMA ALL2820: Chemotherapy-Free Regimen Studied in Front-Line Setting
As front-line therapy, a chemotherapy-free regimen combining the tyrosine kinase inhibitor (TKI) ponatinib and the bispecific T-cell engager blinatumomab significantly outperformed standard treatment with imatinib plus chemotherapy in adults with newly diagnosed Philadelphia chromosome–positive...
Agent Orange Exposure Linked With Risk for Acral Melanoma in Veterans
Exposure to Agent Orange in U.S. veterans was associated with an increased odds of developing acral melanoma compared with controls with and without cutaneous melanoma, according to findings published in JAMA Dermatology. The study authors suggested that there is a need for continued investigation ...
Colorectal Cancer Liver Metastases: Transplant or Resect?
Colorectal metastases isolated to the liver no longer portend a universally fatal outcome. In 2024, the TransMet study1demonstrated that liver transplantation in select patients could be life-saving—thus changing the treatment paradigm—but so can surgical resection when appropriately applied....
ASH 2025: Highlights in Relapsed/Refractory Multiple Myeloma
“Dripping water hollows out stone, not through force but through persistence.” – Ovid The 2025 American Society of Hematology (ASH) Annual Meeting & Exposition delivered multiple practice-changing data sets surrounding T-cell–redirecting therapies in relapsed or refractory multiple myeloma....
Studies Move Away From Whole-Brain Radiotherapy Standard of Care for SCLC
When patients with small cell lung cancer (SCLC) progress, as is common with such an aggressive malignancy, brain metastasis is a known possibility. As such, guidelines have recommended prophylactic cranial irradiation for patients with SCLC who respond well to first-line therapy to decrease the...
Pirtobrutinib Improves Progression-Free Survival vs Bendamustine/Rituximab in Front-Line CLL/SLL
The first prospective, randomized phase III trial of a noncovalent Bruton’s tyrosine kinase (BTK) inhibitor exclusively in treatment-naive patients with chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL)—BRUIN CLL-313—demonstrated a statistically significant and clinically...
Responses to Initial Pembrolizumab Support Treatment De-escalation in Cutaneous Squamous Cell Carcinoma
A response-adapted approach to treatment decision-making for patients with resectable cutaneous squamous cell carcinoma demonstrated that with the use of neoadjuvant pembrolizumab, many patients could avoid surgery and/or radiotherapy. Findings from the De-Squamate study were published in the...
Adjuvant Durvalumab in Resected Early-Stage NSCLC
In a phase III trial (Canadian Cancer Trials Group BR.31) reported in the Journal of Clinical Oncology, Goss et al found that adjuvant durvalumab did not improve disease-free survival vs placebo in patients with completely resected early-stage non–small cell lung cancer (NSCLC). Study Details In...
Advanced NSCLC: Dual vs Single Checkpoint Blockade
A global meta-analysis combined detailed patient data from six major clinical trials to compare two types of immunotherapies for advanced non–small cell lung cancer (NSCLC): dual immunotherapy (a combination of CTLA-4 and PD-1/PD-L1 inhibitors) and single immunotherapy (PD-1/PD-L1 inhibitors...
Updated Analysis of CARTITUDE-4: Ciltacabtagene Autoleucel in Lenalidomide-Refractory Multiple Myeloma
As reported in The Lancet Oncology by Einsele et al, an updated analysis of the phase III CARTITUDE-4 trial has shown that a single infusion of ciltacabtagene autoleucel (cilta-cel), a B-cell maturation antigen–directed chimeric antigen receptor (CAR) T-cell therapy, prolonged overall survival vs...
Addition of Cetrelimab to Erdafitinib in Metastatic Urothelial Carcinoma With FGFR Alterations
In a phase II study (NORSE) reported in the Journal of Clinical Oncology, Loriot et al found that both erdafitinib monotherapy and the combination of erdafitinib and cetrelimab were active as first-line treatment in cisplatin-ineligible patients with metastatic urothelial carcinoma with FGFR...
Nutrition, Muscle Loss Compromises Survival in Patients With Cervical Cancer Undergoing Chemoradiotherapy
A scoping review of cachexia, sarcopenia, and malnutrition in patients with locally advanced cervical cancer undergoing chemoradiotherapy revealed that women who lost at least 10% muscle mass during treatment had a six times higher mortality rate, regardless of their weight at the start of...
Phased Variant ctDNA as Biomarker After First-Line Treatment in LBCL
In a study (DIRECT) reported in the Journal of Clinical Oncology, Krupka et al found that phased variant (PV) ctDNA provided “sensitive and clinically meaningful response assessment” after first-line treatment of large B-cell lymphoma (LBCL). As stated by the investigators, “Tracking tumor-specific ...
Intensity-Modulated Proton vs Photon Radiotherapy in Oropharyngeal Cancer
In a prespecified interim analysis of a phase III trial (University of Texas MD Anderson Cancer Center Clinical Trial Consortium trial) reported in The Lancet, Frank et al found that intensity-modulated proton therapy (IMPT) was noninferior to standard intensity-modulated photon radiation therapy...
Breast Cancer Recurrence Risk Determined by Deep Learning Model Trained on Histopathologic Slides
A deep learning model demonstrated the ability to predict breast cancer recurrence risk and possible benefit from the addition of chemotherapy based on histopathologic images rather than genomic testing in patients with hormone receptor–positive, HER2-negative breast cancer, according to findings...
Addition of Postoperative Nivolumab to Cisplatin and Radiotherapy in High-Risk Locally Advanced HNSCC
In a phase III trial (GORTEC 2018-01, NIVOPOST-OP) reported in The Lancet, Bourhis et al found that the addition of adjuvant nivolumab to cisplatin and radiotherapy improved disease-free survival in patients with high-risk, resected, locally advanced squamous cell carcinoma of the head and neck...
Neoadjuvant SABR Improves Outcomes in Patients With Renal Cell Carcinoma and IVC Tumor Thrombus
Tumor thrombus in the inferior vena cava (IVC) resulting from renal cell carcinoma (RCC) can be safely and effectively treated with stereotactic ablative radiation therapy (SABR) prior to surgery, according to findings from a phase II trial presented at the 26th Annual Meeting of the Society of...
Data Published on Incidence of Immune Checkpoint Inhibitor–Associated ITP
Researchers have published valuable information about a rare but serious complication of cancer immunotherapy, providing the first large-scale description of its risk factors and clinical course and underscoring the importance of early diagnosis and treatment. The findings were published by Leaf et ...
Intravesical Cretostimogene Grenadenorepvec Shows Strong High-Grade Recurrence-Free Survival in BCG-Unresponsive Papillary-Only Non–Muscle-Invasive Bladder Cancer
Intravesical cretostimogene grenadenorepvec (CG0070) monotherapy demonstrated strong high-grade recurrence-free survival rates in patients with high-risk, papillary-only, bacillus Calmette-Guérin (BCG)-unresponsive non–muscle-invasive bladder cancer, according to data presented at the 26th Annual...
KEYNOTE-905: Perioperative Immunotherapy Regimen Active in Cisplatin-Ineligible MIBC
A perioperative regimen of the antibody-drug conjugate enfortumab vedotin-ejfv plus the PD-1 inhibitor pembrolizumab significantly improved event-free survival, overall survival, and pathologic complete response rates compared to radical cystectomy alone in patients with muscle-invasive bladder...
Lifileucel Demonstrates Feasibility and Disease Stability in Advanced Head and Neck Squamous Cell Carcinoma
A single administration of autologous tumor-infiltrating lymphocyte (TIL) cell therapy with lifileucel led to disease stability in patients with recurrent and/or metastatic head and neck squamous cell carcinoma, even among patients whose disease had progressed or did not respond to multiple prior...
ASCO and AI in Oncology: Rooted in Human-Centered Care
ASCO’s mission to conquer cancer through research, education, and promotion of the highest quality patient care requires curiosity, open-mindedness, and an evidence-based approach to emerging technologies. ASCO is committed to helping the oncology community understand, develop, apply, and monitor...
Non–Total Body Irradiation Conditioning Regimen for Young Patients With MRD-Negative B-ALL
Two-year event-free survival rates were above 75% for children, adolescent, and young adult patients with B-cell acute lymphocytic leukemia (B-ALL) who had negative measurable residual disease (MRD) by next-generation sequencing prior to hematopoietic cell transplantation and who received a...
Cyclophosphamide-Based Strategy Enables Safe Transplant From Broadly Mismatched Donors
Clinicians have traditionally prioritized high-level human leukocyte antigen (HLA) matching to minimize graft-vs-host disease (GVHD) after hematopoietic cell transplantation (HCT). New data from the ACCESS study, sponsored by the National Marrow Donor Program, indicate that the use of...
Benefits Mount for TROP2-Directed Antibody-Drug Conjugates in Triple-Negative Breast Cancer
Two randomized phase III trials presented at the European Society for Medical Oncology (ESMO) Congress 2025 bolster support for the use of antibody–drug conjugates—in particular, trophoblast cell surface antigen 2 (TROP2)-targeted agents—as first-line treatments for patients with triple-negative...
LuPSMA-617 Plus Hormone Therapy Improves Radiographic Progression–Free Survival in Metastatic Hormone-Naive Prostate Cancer
The addition of lutetium-177–labeled PSMA-617 (vipivotide tetraxetan; LuPSMA-617), a targeted radionuclide therapy, to standard-of-care androgen-deprivation therapy and an androgen receptor pathway inhibitor appeared to significantly improve radiographic progression–free survival in patients with...
Proton vs Photon Radiation Therapy for Nonmetastatic Breast Cancer: Focus on Patient Perspective and Satisfaction
Health-related quality-of-life analyses for proton radiation therapy and photon radiation therapy in patients with nonmetastatic breast cancer showed similar impacts on quality of life with both treatments, according to findings from the phase III RadComp consortium trial. Shannon M. MacDonald, MD, ...
LuPSMA-617 Plus Hormone Therapy Improves Radiographic Progression–Free Survival in Metastatic Hormone-Naive Prostate Cancer
The addition of lutetium-177–labeled PSMA-617 (vipivotide tetraxetan; LuPSMA-617), a targeted radionuclide therapy, to standard-of-care androgen-deprivation therapy and an androgen receptor pathway inhibitor appeared to significantly improve radiographic progression–free survival in patients with...
FDA Approves Pembrolizumab With Enfortumab Vedotin-ejfv for Muscle-Invasive Bladder Cancer
On November 21, the U.S. Food and Drug Administration (FDA) approved pembrolizumab (Keytruda) or the subcutaneous formulation pembrolizumab and berahyaluronidase alfa-pmph (Keytruda Qlex) in combination with enfortumab vedotin-ejfv (Padcev) as neoadjuvant treatment followed by adjuvant treatment...
Dexrazoxane Use and Cardiovascular Health-Care Utilization in Children With Acute Myeloid Leukemia
In a U.S. cohort study reported as a research letter in JAMA Oncology, Zheng et al found that increasing use of dexrazoxane in newly diagnosed children with acute myeloid leukemia (AML) receiving front-line anthracycline treatment has been accompanied by a reduction in intensive care unit...
Does Regular Opioid Use Increase Risks for Certain Cancers?
Regular pharmaceutical opioid use was found to be associated with an elevated risk for cancers previously associated with opium consumption, but not for other cancers, according to findings from a large-scale study led by the International Agency for Research on Cancer (IARC) that was published in...
Preliminary Activity of LuPSMA-I&T Plus Ra-223 in Metastatic Castration-Resistant Prostate Cancer With Bone Metastasis
In an interim analysis of an Australian single-center phase I/II trial (AlphaBet) reported in The Lancet Oncology, Kostos et al found that the combination of lutetium Lu-177–labeled PSMA–I&T (LuPSMA-I&T) and the bone-seeking alpha-emitter radium Ra-223 dichloride (Ra-223) was active in...
HER3-DXd in Patients With Active Brain Metastases From NSCLC and Breast Cancer
In the phase II TUXEDO-3 trial—reported in two articles in The Lancet Oncology—Fuereder et al and Bartsch et al found that the topoisomerase-1 HER3-targeting antibody-drug conjugate patritumab deruxtecan (HER3-DXd) was active in cohorts of patients with active brain metastases from advanced...
ASCO and ONS Issue First Collaborative Guideline on Extravasation
ASCO and the Oncology Nursing Society (ONS) have released their first joint guideline on managing extravasation, an uncommon but potentially life-threatening complication of intravenous antineoplastic therapy.1 Extravasation occurs when an agent with tissue-damaging properties leaks from the...
Reducing the Impact of Climate-Induced Events on Patients and Oncology Staff
Although 2023 made headlines as the hottest year in human history,1 drawing the world closer to breaching the goals outlined in the Paris Agreement to substantially reduce global greenhouse gas emissions to limit global warming to well below 2°C above preindustrial levels (and preferably to...
